Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company's therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. Its lead therapeutic agent, vodobatinib (SCC-138), is a c-ABL inhibitor that has the potential to be a therapy modulating cellular homeostasis in neurodegenerative diseases. Vibozilimod (SCD-044) is a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist targeting autoimmune disorders. SCD-153 is a topical agent being developed for the treatment of alopecia areata. SBO-154 is an ADC being developed for multiple tumor types expressing MUC-1.